CDR-Life is a biopharmaceutical company redefining antibody therapies to transform the lives of people with sight- and life-threatening diseases. The foundation is a modular antibody fragment platform for composing antibodies with ideal pharmacological and drug-like properties. CDR-Life’s lead programs include trispecific immunotherapies that are highly tumor-selective for increased efficacy and reduced toxicity. The company’s portfolio contains several first-in-class immunotherapies against hematological as well as solid tumor malignancies. CDR-Life partners with pharmaceutical companies to bring these game-changing antibody therapies to patients.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Trispecific antibody against multiple myeloma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):